Hubungan Ekspresi NF-KB pada astrositoma dengan sistem klasifikasi WHO dan Luaran di RSUP. H. Adam Malik Medan tahun 2015.

DAFTAR PUSTAKA
Atkinson, G. P., Nozell, S. E., & Benveniste, E. T. N. (2010). NF-κB and STAT3 signaling in
glioma: targets for future therapies. Expert Review of Neurotherapeutics, 10(4), 575–586.
http://doi.org/10.1586/ern.10.21
Colen, C. B., & Allcut, E. (2012). Quality of life and outcomes in glioblastoma management.
Neurosurgery

Clinics

of

North

America,

23(3),

507–513.

http://doi.org/10.1016/j.nec.2012.04.010
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., et al.

(2007). Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes &
Development, 21(21), 2683–2710. http://doi.org/10.1101/gad.1596707
Hayasshi,S., Yamamoto, M., Ueno, Y., Ikeda, K., Ohsima, K., Soma, G.-I., & Fukushima, T.
(2001). Expression of Nuclear Factor-κB, Tumor Necrosis Factor Receptor Type 1, and
c-Myc in Human Astrocytomas. Neurologia Medico-Chirurgica, 41(4), 187–195.
http://doi.org/10.2176/nmc.41.187
Hentschel, S. J., & Lang, F. F. (2003). Current Surgical Management of Glioblastoma. The
Cancer Journal, 9(2).
Ishkanian, S., Laperriere, N. J., Xu, W., et al. (2011). Upfront observation versus radiation for
adult pilocytic astrocytoma. Cancer, 117(17): 4070-9.
Kim, Y.-H., & Kim, C.-Y. (2012). Current surgical management of insular gliomas.
Neurosurgery

Clinics

of

North

America,

23(2),

199–206–

vii.

http://doi.org/10.1016/j.nec.2012.01.010
Korkolopoulou, P., Levidou, G., Saetta, A. A., El-Habr, E., Eftichiadis, C., Demenagas, P., et
al. (2008). Expression of nuclear factor-κB in human astrocytomas: relation to pIκBa,
vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival.
Human Pathology, 39(8), 1143–1152. http://doi.org/10.1016/j.humpath.2008.01.020

Universitas Sumatera Utara

Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., et al.
(2007). The 2007 WHO Classification of Tumours of the Central Nervous System. Acta
Neuropathologica, 114(2), 97–109. http://doi.org/10.1007/s00401-007-0243-4
McLendon, R., Friedman, A., Bigner, D., Van Meir, E. G., Brat, D. J., M Mastrogianakis, G.,
et al. (2008). Comprehensive genomic characterization defines human glioblastoma

genes

and

core

Nature,

pathways.

455(7216),

1061–1068.

http://doi.org/10.1038/nature07385
Nagasawa, D. T., Chow, F., Yew, A., Kim, W., Cremer, N., & Yang, I. (2012).
Temozolomide and Other Potential Agents for the Treatment of Glioblastoma
Multiforme.

Neurosurgery

Clinics

of

North

America,

23(2),

307–322.

http://doi.org/10.1016/j.nec.2012.01.007
Ohgaki, H., & Kleihues, P. (2013). The definition of primary and secondary glioblastoma.
Clinical Cancer Research, 19(4), 764–772. http://doi.org/10.1158/1078-0432.CCR-123002
Omuro, A. (2013). Glioblastoma and Other Malignant Gliomas. Jama, 310(17), 1842–9.
http://doi.org/10.1001/jama.2013.280319
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., et al. (2013).
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors

Diagnosed in the United States in 2006-2010. Neuro-Oncology, 15(suppl 2), ii1–ii56.
http://doi.org/10.1093/neuonc/not151
Puliyappadamba, V. T., Hatanpaa, K. J., Chakraborty, S., & Habib, A. A. (2014). The role of
NF-κB in the pathogenesis of glioma. Molecular & Cellular Oncology, 1(3), e963478.
http://doi.org/10.4161/23723548.2014.963478
Reardon, D. A. (2006). Therapeutic Advances in the Treatment of Glioblastoma: Rationale
and

Potential

Role

of

Targeted

Agents.

The

Oncologist,

11(2),

152–164.

Universitas Sumatera Utara

http://doi.org/10.1634/theoncologist.11-2-152
Taw, B. B. T., Gorgulho, A. A., Selch, M. T., & De Salles, A. A. F. (2012). Radiation options
for high-grade gliomas. Neurosurgery Clinics of North America, 23(2), 259–67– viii.
http://doi.org/10.1016/j.nec.2012.01.003
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., et al.
(2010). Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of
Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Cancer Cell, 17(1), 98–110. http://doi.org/10.1016/j.ccr.2009.12.020

Universitas Sumatera Utara